SEATTLE, Nov. 24, 2014 /PRNewswire/ -- Adaptive Biotechnologies, a pioneer in leveraging Next Generation Sequencing (NGS) to profile T- and B-cell receptors, today launched a research use only Kit of the Company's flagship immunoSEQTM platform technology. The launch of the immunoSEQ Kit is a breakthrough event for researchers of any immune-mediated disease, including cancer, autoimmune disorders, and infectious diseases, who are seeking highly quantitative and reliable measurements of T-cell Receptor Beta (TCRB) repertoires.
The advent of the immunoSEQ Kit allows researchers with Illumina® sequencing machines, to perform T-cell sequencing and bioinformatics analyses conveniently in their own labs, with only four hours of hands-on time, and still leverage the same proprietary advanced bioinformatics software that immunoSEQ Service customers receive. Importantly, the immunoSEQ Kit incorporates the proprietary, patent-pending methodology developed by Adaptive to control for PCR amplification bias, which is critical to ensure reproducible, quantitative results. Prior to availability of the Kit, researchers had to send DNA from tissue and blood samples to Adaptive's Seattle-based state-of-the-art sequencing laboratory to get these data.
"Adaptive's goal from the start was to enable researchers to make great discoveries by leveraging the groundbreaking data that immunosequencing offers. After years of refining our assay to ensure truly standardizable, consistent results every time, we are thrilled to be able to distribute this tool as widely as possible, so that more discoveries can be made as quickly as possible," explains Chad Robins, CEO and Founder of Adaptive Biotechnologies.
Since 2009, the immunoSEQ Assay has been used by hundreds of researchers from academic and research institutions, and pharmaceutical companies, across more than 20 countries. Prior to launch, the company completed a beta test for the immunoSEQ Kit at multiple large academic medical centers around the United States. In the beta test, the same biological sample was analyzed by different institutions, and the immunoSEQ Kit reproducibly reported the frequency of each clonal population of T cells from lab to lab.
"The consistency of the sequencing data across the beta centers was remarkable and sets the stage for the immunoSEQ Kit to become the standard for reliable, consistent data," said Dr. Harlan Robins, Chief Scientific Officer and Founder of Adaptive. "We are excited to see the breadth and depth of studies that researchers will conduct using this new tool under their control and at their convenience."
The Company intends to launch additional research use only immunoSEQ Kits for B-cell receptors and other specific receptor loci, and to expand distribution internationally in 2015. Adaptive's innovative immunosequencing tools will position the company as a leader in the development of future clinical kits for each of the company's diagnostic offerings. The first clinical kit in development is a clonoSEQTM Kit for measuring Minimal Residual Disease in blood cancers, which is currently offered as a Laboratory Developed Test (LDT) in the company's CLIA-certified lab in Seattle.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages NGS to profile T-Cell and B-Cell Receptors. This breakthrough enables in-depth characterization of the adaptive immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis and monitoring of cancer patients.
Adaptive helps researchers make discoveries in oncology, autoimmune disorders and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology under the immunoSEQTM brand name. The immunoSEQTM Kit for research use only is now available to facilitate the integration of immunosequencing into research centers. The immunoSEQ Assay is not for use in diagnostic procedures.
Adaptive uses its proprietary immunosequencing platform to validate clinical diagnostics in cancer and other immune-mediated diseases. The company's first CLIA certified clinical application, the clonoSEQTM Assay, is used to monitor Minimal Residual Disease (MRD) in blood-based cancers. Improving the ability to accurately detect and track residual disease at a molecular level affords clinicians the potential to detect relapse earlier and improve patient care.
The company is currently validating the tilSEQTM Assay, a second novel oncology diagnostic to quantify the presence and clonality of Tumor Infiltrating Lymphocytes ("TILs") and to create a reliable measure of "immunocompetency" to predict or monitor response to cancer treatments that directly alter the host immune system.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/adaptive-biotechnologies-launches-the-immunoseq-kit-to-enable-researchers-to-sequence-the-adaptive-immune-system-in-their-own-labs-300000509.html
SOURCE Adaptive Biotechnologies Corp.